Status:
COMPLETED
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)
Lead Sponsor:
Sirion Therapeutics, Inc.
Conditions:
Inflammation
Eligibility:
All Genders
2+ years
Phase:
PHASE3
Brief Summary
The purpose of this phase III study is to determine the safety and efficacy of difluprednate in the management of inflammation following ocular surgery.
Eligibility Criteria
Inclusion
- Scheduled for unilateral ocular surgery.
Exclusion
- Systemic administration of any corticosteroid or immunosuppressive drug in the 2 weeks prior to study enrollment.
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2008
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00616070
Start Date
December 1 2007
End Date
March 1 2008
Last Update
June 30 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charlotte Eye, Ear, Nose & Throat
Charlotte, North Carolina, United States, 28210